Asthma: developments in targeted therapy

Despite advances in long-term management, asthma remains a health problem in industrialized countries. Even if the updated guidelines continues to emphasize that the most effective medications for long-term asthma therapy are inhaled corticosteroids, the actual pharmacological therapies are unable to modify the natural course of ‘asthma history’, so there is an urgent need for targeted, diseasemodifying asthma treatments [1]. The definition of the pathogenic mechanisms of asthma has opened the way to new therapeutic strategies. In the present article, we briefly discuss the past, present and particularly the future perspectives of targeted asthma therapies. However, it is now accepted that there are distinct asthma phenotypes, and that available therapeutic approaches may only interfere with some aspects of the disease process [2].

[1]  S. Holgate.  Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches? , 2011, The Journal of allergy and clinical immunology.

[2]  A. Matucci,et al.  Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management , 2011, Current opinion in allergy and clinical immunology.

[3]  D. Price,et al.  Leukotriene antagonists as first-line or add-on asthma-controller therapy. , 2011, The New England journal of medicine.

[4]  I. Pavord,et al.  Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial , 2010, European Respiratory Journal.

[5]  Lorin Roskos,et al.  A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma , 2010, BMC pulmonary medicine.

[6]  E. Kerwin,et al.  A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. , 2009, American journal of respiratory and critical care medicine.

[7]  W. Busse,et al.  Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study , 2008, Allergy.

[8]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[9]  S. Wenzel.  Asthma: defining of the persistent adult phenotypes , 2006, The Lancet.

[10]  W. Busse,et al.  Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. , 2003, The Journal of allergy and clinical immunology.

[11]  M. Brigham-Burke,et al.  Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti‐interleukin‐4 antibody with therapeutic potential in asthma , 2002, Clinical and experimental immunology.

[12]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[13]  C. Brightling,et al.  Targeting TNF-α: A novel therapeutic approach for asthma , 2008 .

[14]  F. Kalkbrenner,et al.  Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma. , 2007, American journal of respiratory cell and molecular biology.